TB-500

TB-500 (also known as Thymosin Beta-4 fragment, Tβ4) is a prominently researched experimental compound classified strictly within the Thymosin Beta-4 Fragment framework. Operating primarily through advanced pharmacological pathways, it functions by upregulates actin for cell migration and wound healing. Reduces inflammation, encourages new blood vessel growth, and supports stem cell maturation for tissue repair. with a documented biological half-life of roughly 2 hours, in preclinical investigative trials and independent academic studies, researchers utilizing TB-500 have documented significant, quantifiable biological outcomes, primarily focusing on muscle/tissue repair, flexibility, injury recovery. Typical research protocols investigate administering 2500 to 2500mcg via subq pathways 2x/wk. However, it is critically important to understand that while TB-500 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.